Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Eli Lilly (NYSE:LLY) reported its Q1 2025 ... “neutral” later on would be if a competitor enters the obesity drug treatment market space and starts to eat away at its market share.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.